We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Tamiflu hullabaloo

19 October 2005 By Robert Cyran

The Swiss drugmaker can t keep up with demand for its flu treatment amid fears of a pandemic. And sales of its cancer drugs are booming. But the real story behind the Q3 sales update is that margins are almost certainly rising sharply.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)